Other than the rodents, SDGR may be the biggest beneficiary of FDA’s new policy on animal testing: https://www.businesswire.com/news/home/20250414202065/en/Schrdingers-Statement-Regarding-FDA-Plan-to-Phase-Out-Animal-Testing-Requirement-for-Monoclonal-Antibodies-and-Other-Drugs Investors have noticed—the stock is up 40% since Thursday.